Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Mac... ( NEW ORLEANS La. Nov. 10 /- Ellex ...)

Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema

Date:11/10/2007

NEW ORLEANS, La., Nov. 10 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, announced today initial clinical results of an ongoing study for non-thermal Retina Regeneration Therapy (Ellex 2RT(TM)). Results demonstrate the therapy's potential to improve and stabilize visual acuity and to reduce retinal edema in patients with diabetic maculopathy and macular edema without causing any damage to the photoreceptors.

Peter Hamilton, MD, FRCOph, the principal clinical investigator in the Ellex 2RT research program at St. Thomas Hospital, London, presented the initial clinical trial results today at the Retina Subspecialty Day of the annual meeting of the American Academy of Ophthalmology (AAO).

"The first phase clinical outcomes have confirmed Ellex 2RT's ability to treat diabetic maculopathy without damaging the neuro-retina," commented Professor John Marshall, principal investigator of the Ellex 2RT research program. "This means that Ellex 2RT may change the way diabetic maculopathy patients are treated and it shows potential for intervention in early stage Age-Related Macular Degeneration (AMD) before significant loss of vision has occurred."

"We are encouraged by the first patient data presented today as it provides the assurance we were looking for to expand Ellex 2RT research," commented Peter Falzon, Ellex CEO. "The next phase clinical trials will be essential in establishing Ellex 2RT's potential as an early stage therapy for retinal diseases."

ABOUT THE CLINICAL TRIAL

The clinical trials are conducted under the direction of Professor John Marshall, Ph.D., FRCPath, who is Frost Professor of Ophthalmology at the Rayne Institute and Head of the Academic Department of Ophthalmology at King's College, University of London.

The prospective study, which includes 18 patients (29 eyes) was designed to evaluate the effectiveness of sele
'/>"/>

SOURCE Ellex Medical Lasers Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:

(Date:5/24/2013)... 2013 /PRNewswire-iReach/ -- Phoenix Houses of California ... organization, is hosting its tenth annual "Triumph For Teens" ... 6, 2013. More than 300 people are expected to ... residential treatment centers, family therapy, and prevention programs of ... have positive influences on the health and welfare of our ...

(Date:5/24/2013)... , May 24, 2013 Heska Corporation (NASDAQ: HSKA, ... and specialty products, announced today that Dr. Robert ... and Jason Napolitano , executive vice president ... Marcum MicroCap Conference, which is being held May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

[0] Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg [0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

... Amgen (Nasdaq: AMGN ) today announced results ... treatment for advanced cancer patients with bone metastases in ... (zoledronic acid). These results underscore the efficacy profile of ... bone metastases from advanced breast cancer, as well as ...

... Dec. 10, 2010 Syndax Pharmaceuticals, Inc., a clinical-stage ... on entinostat, an orally bioavailable, highly selective, class I ... cancer. The data are being presented as oral poster ... 8 through December 12 in San Antonio Texas. ...

Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer

(Date:5/24/2013)... Compromise is often cited as crucial for relationships, ... sleep and comfort. However, many couples find themselves facing dilemmas ... this can cause added stress, lost sleep, and some resentment. ... common issues in their latest article on the subject. ... What to do When You Disagree on the Best Mattress ...

(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... the 2010 DePuy hip recall continue to move forward ... According to documents filed in California’s San Francisco ... been seeking an expedited trial of her DePuy hip ... (Tilman v. DePuy Orthopaedics, Inc., et al., No. CGC11508806; ...

(Date:5/24/2013)... 24, 2013 KC and Monica Craichy, Founders ... for FreeRide836. Their oldest sons, Kyle and Austin Craichy, will ... family and several professional kiteboarders. , KC Craichy said he ... has miraculously come together such that virtually everyone who planned ... , 20 kite boarders will meet at Matheson Hammock Park ...

(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...

(Date:5/24/2013)... Teams of highly respected Alzheimer,s researchers failed to replicate ... of this brain disease when they were published last ... results, presented online Feb. 9, 2012, suggested that the ... buildup of beta amyloid plaques (Aβ) a pathological ... mice. According to the authors of the 2012 report, ...

Breaking Medicine News(10 mins):Health News:What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples 2 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 2 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 3 Health News:DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case 4 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2 Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2 Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3

[0] What’s The Best Bed Offers Mattress & Sleep Solutions for Opposite Couples [0] DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for Voluntary Dismissal in California DePuy Hip Recall Case [0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 [0] Multiple research teams unable to confirm high-profile Alzheimer's study

... Ceftaroline Met Primary Objective and Achieved High Clinical Cure Rates ... , NEW YORK, June 19, 2009 Forest Laboratories, ... from two global multi-center Phase III studies of ceftaroline for ... data in each of the pivotal trials (FOCUS I and ...

... Kenneth A. May, former CEO of FedEx Kinko,s, has been ... Dimes, it was announced today. , , "Ken May is ... Prematurity Campaign," said Dr. Jennifer L. Howse, President of the March ... work towards our goal of giving every baby a healthy start ...

... changes , FRIDAY, June 19 (HealthDay News) -- A key ... by British researchers, who suggest that their finding may lead ... King,s College London and Imperial College London helps explain why ... are remodeled and how these changes contribute to chronic asthma. ...

... The Center for Laser Surgery, Washington, DC has announced the ... recently FDA approved, is the first cosmetic neurotoxin available alongside ... The Center for Laser Surgery was ... Dysport. As Washington, DC, Maryland and Virginia,s largest and most ...

... , WASHINGTON, June 19 The Department of Veterans Affairs ... its award-winning health care system, is poised to welcome nearly ... the country by expanding access to health care enrollment for ... , , "This incremental approach to expanding enrollment ensures ...

... should be treated as a priority if offenders held in ... research from the University of Adelaide, Australia. Adelaide researchers ... health of young offenders undertaken in the USA, UK, Europe ... have been published in this month,s Australian Journal of ...

Cached Medicine News:Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4 Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5 Health News:Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative 2 Health News:VA Reopening Health Care Enrollment to Thousands of Veterans 2 Health News:Young offenders' health critical to rehabilitation 2 Health News:Young offenders' health critical to rehabilitation 3

Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization Ken May Re-Elected for Second Term as Chairman of the Board of March of Dimes Asthma Discovery May Lead to Better Treatments Dysport Available! New Wrinkle Treatment in Washington, DC Offers Botox Alternative VA Reopening Health Care Enrollment to Thousands of Veterans Young offenders' health critical to rehabilitation

The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....

... accelerators are true high-performance ... multileaf collimation and electronic ... enable you to perform ... IMRT treatments, as well ...

... Clinac EX accelerators ... with integrated Varian multileaf ... imaging systems which enable ... most advanced computer-driven IMRT ...

The Clinac C family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....

Medicine Products:

Primus Linear Accelerator Clinac 23EX Clinac 21EX Clinac C